 |
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/43054
Bayer: Performance, Products, Pipeline and Potential
|
Description: |
Bayer is a global enterprise, headquartered in Germany, with core competencies in the fields of healthcare, nutrition and high-tech materials, and organised into three subgroups, namely HealthCare, CropScience and MaterialScience. Following Bayer's acquisition of Schering AG on 23rd June 2006, Schering was renamed Bayer Schering Pharma and its integration into the Pharmaceuticals division of Bayer HealthCare is now under way. Bayer Schering Pharma is expected to contribute to over half the revenues of Bayer HealthCare.
Bayer HealthCare's combined pharmaceuticals business is characterised by a well-balanced portfolio comprised of business units such as oncology, cardiology/haematology and gynaecology. In addition, the combined biotech platform provides a sound basis for further growth, including such products as Schering's Betaseron (interferon beta-1b) and Leukine (sargramostim), together with Bayer’s genetically-engineered Factor VIII Kogenate. Current growth drivers include: Avalox/Avelox (moxifloxacin), Betaferon/Betaseron (interferon beta-1b), Kogenate (Factor VIII), Levitra (vardenafil), Mirena (levonorgestrel), Yasmin (ethinyloestradiol+drospirenone) and Aspirin Cardio. By combining and consolidating the research and development activities of the two companies Bayer has achieved a more focused and balanced pipeline.
The acquisition of Schering AG, the largest corporate transaction in Bayer's history, enhanced the product portfolio and research and development pipeline providing a strong basis on which to build future success for Bayer HealthCare and thus the Bayer Group. Bayer is expecting HealthCare to account for nearly 50 per cent of Group sales in the future.
The integration of Schering is proceeding faster than expected and the acquisition has strengthened the Bayer Group's global market position in the pharmaceutical business as it copes with declining sales for many of its previously top-selling products, specifically Cipro.
Bayer's overall strategy of focusing its portfolio has continued with the divestment of the diagnostics business to Siemens Medical Solutions, followed by the subsidiaries of HC Starck and Wolff Walsrode. Since Bayer has acquired a diagnostics imaging business with the acquisition of Schering, this would seem to be a possible candidate for divestiture in the future.
The withdrawal of Trasylol is a notable setback for the company, especially following the withdrawal of Baycol/Lipobay around six years earlier. Both products managed to reach the market despite safety issues that subsequently led to withdrawal. This has led to company-wide review of Bayer Schering’s development and review processes. These two incidents occurring in such a short space of time could have some impact on Bayer’s profile in the pharmaceutical market.
This new strategic analysis report Bayer: Pipeline, Products, Performance, Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price. |
|
Contents: |
Latest Results
EXECUTIVE SUMMARY
Introduction
Financial Performance 2009
Business Segment Performance
Company Strategy
Research and Development Strategy
Key Agreements
Mergers, Acquisitions and Divestitures
Manufacturing
Employees
Product Performance Forecasts
Pipeline Analysis
Discontinued Projects
Other Factors Affecting The Bottom Line
Conclusions/Outlook
THERAPEUTIC AREA FOCUS
R&D PIPELINE
PRIMARY CARE
Marketed Products
Avelox
Azlin
Baypen
Biltricide
Canesten
Cipro
Diastabol
Fosrenol
Glucobay
Levitra
Mycospor
Nimotop
Pro-viron
R&D Projects
NKTR-061
WOMEN'S HEALTHCARE
Marketed Products
Angeliq
Fidencia
Cliane
Climara
Climodien 2/2 / Climodien 1/2
Diane
Menostar
Microgynon
Natazia
Nuvelle TS
Primolut
Qlaira
Tetragynon
Valette
R&D Projects
SPECIALIZED THERAPEUTICS
Marketed Products
Betaseron
Cipramil
Dopergin
Noctamid
Sativex
R&D Projects
VEGF Trap-Eye
HAEMATOLOGY / CARDIOLOGY
Marketed Products
Adalat
Baypress
Betapace
Kogenate
Quinaglute
Recothrom
Refludan
Syscor
Ventavis
Xarelto
R&D Projects
Riociguat
ONCOLOGY
Marketed Products
Bonefos
Depostat
Nexavar
Primoteston Depot
Zevalin
R&D Projects
Alpharadin
Antiprogestin
L19
Regorafenib
Sagopilone
APPENDIX 1 - FINANCIAL PERFORMANCE
Full Year Results 2009
APPENDIX 2 - KEY AGREEMENTS
Abbott
Actimis Pharmaceuticals
Activaero Technologies GmBH
Algeta ASA
Amerinet Inc
Ardea Biosciences Inc
Asklepios Biopharmaceutical Inc
Astex Technology
AstraZeneca
Avid Radiopharmaceuticals Inc
Barr Laboratories Inc
Biogen Idec/Cell Therapeutics Inc
Bioton SA
Boehringer Ingelheim
Celera Genomics
Cell Therapeutics Inc
ChemDiv Inc
CoTherix Inc
CSL Behring
CuraGen Corporation
Cytogen Corporation
Daiichi Sankyo
DARA Biosciences Inc
deCODE genetics
Dyax Corporation
E-Z-EM Inc
EPIX Pharmaceuticals
First Horizon Pharmaceutical Corporation
Favrille Inc
Fresenius Kabi AG
Genstruct Inc
Genzyme Corporation
GlaxoSmithKline
GW Pharmaceuticals plc
Indevus Pharmaceuticals Inc
ImmunoGen Inc
Johnson & Johnson
Mallinckrodt Inc
Memory Pharmaceuticals Inc
Micromet Inc
Millennium Pharmaceuticals Inc
Mitsubishi Tanabe Pharma
Monash University
Morphosys AG
Nektar Therapeutics Corporation
Novartis
OncoGeneX Pharmaceuticals Inc
Onyx Pharmaceuticals Inc
Peregrine Pharmaceuticals Inc
Pfizer
Philogen Srl
ProStrakan Group Plc
Ranbaxy Laboratories Limited
Regeneron Pharmaceuticals Inc
sanofi-aventis
Schering-Plough
Shionogi
Siemens Medical Solutions
Stanford University
Syndax Pharmaceuticals Inc
Taisho Pharmaceutical
Titan Pharmaceuticals
Vaccinex Inc
Warner Chilcott
Xanthus Pharmaceuticals Inc
Zilip-Pharma
ZymoGenetics Inc
APPENDIX 3 - INFRASTRUCTURE
Research and Development Facilities
Manufacturing Facilities
APPENDIX 4 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES
Subsidiaries
Joint-venture Companies
APPENDIX 5 - PRODUCT INDEX
List of Tables:
Principal Operating Results
Capital Expenditure by Business Area
Capital Expenditure by Geographic Area
Research and Development Expenditure by Business Area
Research and Development by Geographic Area
Sales by Business Area
Operating Income (Loss) by Business Area
Sales by Destination
Sales by Origin
Operating Income (Loss) by Geographical Area
Recent Product Approvals
Major Products, Therapeutic Areas And Sales
Avalox/Avelox Sales by Company (2008-2016)
Levitra Sales by Company (2008-2016)
Interferon Beta-1b Sales by Company (2008-2016)
Xarelto Sales by Company (2008-2016)
Riociguat Sales (2012-2016)
Nexavar Sales by Indication (2008-2016)
Alpharadin Sales by Indication (2013-2016)
List of Charts:
Sales, Costs and Operating Income
Capital Expenditure by Business Area, 2009
Research and Development by Geographic Area, 2009
Sales by Business Area, 2009
Operating Income by Business Area
Sales by Destination
Operating Income by Geographical Area
Sales of Current Major Products (2008-2016)
Sales By Major Product, 2009
Avalox/Avelox Sales by Company (2008-2016)
Bayer's Sales of Cipro/Ciprobay (2008-2016)
Glucobay Sales (2008-2016)
Levitra Sales by Company (2008-2016)
Interferon Beta-1b Sales by Company (2008-2016)
Bayer's Sales of Adalat (2008-2016)
Kogenate Sales (2008-2016)
Xarelto Sales by Company (2009-2016)
Riociguat Sales (2012-2016)
Nexavar’s Dual Mode of Action
Nexavar Total Sales (2008-2016)
Nexavar Sales by Indication, 2009
Nexavar Sales by Indication, 2016
Alpharadin Sales (2013-2016)
Sales, Costs and Operating Income
Profitability and Research Ratios
R&D Expenditure and Capital Expenditure
Current Assets, Liabilities and Ratio
Assets, Cash and Liquidity
Employees and Productivity |
|
Companies Mentioned |
- Abbott
- Actimis Pharmaceuticals
- Activaero Technologies GmBH
- Algeta ASA
- Amerinet Inc
- Ardea Biosciences Inc
- Asklepios Biopharmaceutical Inc
- Astex Technology
- AstraZeneca
- Avid Radiopharmaceuticals Inc
- Barr Laboratories Inc
- Biogen Idec/Cell Therapeutics Inc
- Bioton SA
- Boehringer Ingelheim
- Celera Genomics
- Cell Therapeutics Inc
- ChemDiv Inc
- CoTherix Inc
- CSL Behring
- CuraGen Corporation
- Cytogen Corporation
- Daiichi Sankyo
- DARA Biosciences Inc
- deCODE genetics
- Dyax Corporation
- E-Z-EM Inc
- EPIX Pharmaceuticals
- First Horizon Pharmaceutical Corporation
- Favrille Inc
- Fresenius Kabi AG
- Genstruct Inc
- Genzyme Corporation
- GlaxoSmithKline
- GW Pharmaceuticals plc
- Indevus Pharmaceuticals Inc
- ImmunoGen Inc
- Johnson & Johnson
- Mallinckrodt Inc
- Memory Pharmaceuticals Inc
- Micromet Inc
- Millennium Pharmaceuticals Inc
- Mitsubishi Tanabe Pharma
- Monash University
- Morphosys AG
- Nektar Therapeutics Corporation
- Novartis
- OncoGeneX Pharmaceuticals Inc
- Onyx Pharmaceuticals Inc
- Peregrine Pharmaceuticals Inc
- Pfizer
- Philogen Srl
- ProStrakan Group Plc
- Ranbaxy Laboratories Limited
- Regeneron Pharmaceuticals Inc
- sanofi-aventis
- Schering-Plough
- Shionogi
- Siemens Medical Solutions
- Stanford University
- Syndax Pharmaceuticals Inc
- Taisho Pharmaceutical
- Titan Pharmaceuticals
- Vaccinex Inc
- Warner Chilcott
- Xanthus Pharmaceuticals Inc
- Zilip-Pharma
- ZymoGenetics Inc |
|
Ordering: |
Order Online - visit http://www.researchandmarkets.com/reports/43054
Order by Fax - using the order form below
Order By Post - print the order form below and send to
|
|
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
 |
Page 1 of 2
Printed 12/02/2012 18:03:02 |
|
Fax Order Form
To place an order via fax simply print this form, fill in the information below and
fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
|
|
|
|
Product Name: |
Bayer: Performance, Products, Pipeline and Potential
|
|
Web Address: |
http://www.researchandmarkets.com/reports/43054
|
|
Office Code: |
|
OC8IHINLSNNSS
|
Report formats
Please enter the quantity of the report format you require.
|
|
Format
|
Quantity
|
Price
|
|
Hard Copy
|
|
€745.00 + EUR€ 50.00 Shipping/Handling *
|
|
Electronic (PDF)
- Single User
|
|
€745.00
|
|
Online Access
- Enterprisewide
|
|
€4,850.00
|
|
Electronic (PDF)
- Enterprisewide
|
|
€4,850.00
|
|
Online Access
- Single User
|
|
€745.00
|
* Shipping/Handling is only charged once per order.
Contact information
Please enter all the information below in BLOCK CAPITALS.
|
|
|
First Name: |
Last Name: |
|
Email Address: |
|
|
Job Title: |
|
|
Organisation: |
|
|
Address: |
|
|
City: |
|
|
Postal/Zip Code: |
|
|
Country: |
|
|
Phone Number: |
|
|
Fax Number: |
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
|
|
Page 2 of 2
Printed 12/02/2012 18:03:02
|
|
Payment information
Please indicate the payment method you would like to use by selecting the appropriate
box.
|
|
|
|
|
American Express
|
|
|
Diners Club
|
|
|
Master Card
|
|
|
Visa
|
|
|
|
|
|
|
Cardholder's Name: |
|
|
|
|
Cardholder's Signature: |
|
|
|
|
Expiry Date: |
/ |
|
|
|
Card Number: |
|
|
|
|
CVV Security Code: |
|
|
|
|
Issue Date: |
/ (Diners
Club only)
|
|
|
|
|
|
|
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
|
|
|
|
Please transfer funds to:
|
|
|
Account number: |
83313083 |
|
Sort code: |
98-53-30 |
|
Swift code: |
ULSBIE2D |
|
IBAN number: |
IE78ULSB98533083313083 |
|
Bank Address: |
Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland. |
|
|
|
If you have a Marketing Code please enter it below:
|
|
|
Marketing Code: |
|
|
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
|
|
|
|
|
|
